This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection
by Kinjel Shah
A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals
4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
by Kinjel Shah
Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.
4 Top Biotech Stocks to Buy in the Time of Coronavirus
by Tirthankar Chakraborty
We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.
Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts
by Zacks Equity Research
Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.
Pfizer (PFE) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Pfizer (PFE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Inovio (INO) Posts Wider Q4 Loss, Gets COVID-19 Vaccine Grant
by Zacks Equity Research
Inovio's (INO) loss in the fourth quarter falls shy of estimates and revenues too miss the mark. The company is focused on developing INO-4800, its DNA vaccine, against COVID-19.
Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.
Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.
BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
The Zacks Analyst Blog Highlights: REGN, ENPH, SFM, DPZ and VNET
by Zacks Equity Research
The Zacks Analyst Blog Highlights: REGN, ENPH, SFM, DPZ and VNET
Vir (VIR) Looks Good: Stock Adds 12.9% in Session
by Zacks Equity Research
Vir (VIR) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure
by Zacks Equity Research
AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment
5 of the Best Coronavirus-Proof Stocks to Invest In Now
by Sreoshi Bera
With coronavirus cases on the rise, lack of labor and supply chain disruption are impacting businesses worldwide. However, certain industries could offer healthy returns on investment.
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Buckle, Chipotle Mexican Grill, Co-Diagnostics, Moderna and Regeneron Pharmaceuticals
5 Top Low-Beta Stocks Flying High Despite Severe Volatility
by Nalak Das
A few low-beta (beta value less than 1 but greater than zero) stocks have actually recorded strong gain since these are less volatile than the broader market.
3 Stocks With Recent Price Strength Despite Market Turmoil
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Stocks to Win Big From Trump's Economic Stimulus
by Tirthankar Chakraborty
Trump floats financial aids to counter the impact of the coronavirus outbreak. Notable stimulus measures include payroll tax cut, aid for wage earners and an emergency funding worth $8.3 billion
How to Invest in a Volatile Market Amid a Stable U.S. Economy
by Nalak Das
Despite the virus-driven global disturbance, the U.S. economy remains stable as indicated by recently released various data for the month of February.
Volatility Skyrockets: Global Week Ahead
by John Blank
Sure, central banks are slashing interest rates, but jump-starting the economic recovery might need large doses of government spending as well, in the form of tax breaks, infrastructure, welfare and so on.
Arena's Pipeline Holds Promise, Plunging Revenues a Concern
by Zacks Equity Research
Arena (ARNA) has sufficient funds to support its pipeline progress. However, competitive targeted indications and plunging revenues raise concerns.
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
Why Is Regeneron (REGN) Up 26.8% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.